Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Other financing activities (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Other financing activities for 2 consecutive years, with $11.9 million as the latest value for Q4 2025.

  • Quarterly Other financing activities fell 43.9% to $11.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.0 million through Dec 2025, down 43.35% year-over-year, with the annual reading at $11.9 million for FY2025, 44.19% down from the prior year.
  • Other financing activities hit $11.9 million in Q4 2025 for Prelude Therapeutics, up from $2.4 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $21.2 million in Q4 2024 to a low of $2.4 million in Q3 2025.